未找到相关数据
Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients.
被引：11
作者：
Andreeff, Michael
Borthakur, Gautam
Zeng, Zhihong
Kelly, Mary A.
Wang, Rui-Yu
McQueen, Teresa J.
Qiu, Yihua
Mak, Duncan
Burger, Jan Andreas
Daver, Naval Guastad
Pemmaraju, Naveen
Kadia, Tapan M.
Jabbour, Elias
Pierce, Sherry
Ravandi, Farhad
Garcia-Manero, Guillermo
O'Brien, Susan Mary
Cortes, Jorge E.
Kantarjian, Hagop M.
Konopleva, Marina
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.7033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7033
引用
收藏
页数：1
相关论文